A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

MLA

Heaney, Nicholas, et al. “A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.” Blood, vol. 110, no. 11, Nov. 2007, p. 1033. EBSCOhost, https://doi.org/10.1182/blood.V110.11.1033.1033.

APA

Heaney, N., Drummond, M., Kaeda, J., Nicolini, F., Clark, R., Wilson, G., Shepherd, P., Tighe, J., McLintock, L., Hughes, T., & Holyoake, T. L. (2007). A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib. Blood, 110(11), 1033. https://doi.org/10.1182/blood.V110.11.1033.1033

Chicago

Heaney, Nicholas, Mark Drummond, Jaspal Kaeda, Franck Nicolini, Richard Clark, George Wilson, Pat Shepherd, et al. 2007. “A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.” Blood 110 (11): 1033. doi:10.1182/blood.V110.11.1033.1033.